Abstract
Oxcarbazepine is a new anticonvulsant with an active metabolite. It is approved as mono- or adjunctive therapy for partial seizures in adults and children older than 4 years of age and as adjunctive therapy in children 2 years and older. Its spectrum of anticonvulsant activity is comparable to carbamazepine, but it has an improved pharmacokinetic profile, is better tolerated and is associated with few clinically significant drug-drug interactions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Pediatric Pharmacology and Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
